OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Communications is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
	602
	416
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor	375
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”	335
Issue Information	334
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation	288
Issue Information	259
Issue Information	231
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma	187
Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation	180
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort	172
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study	170
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update	162
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives	159
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity	157
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy	148
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study	143
Current status and perspectives of esophageal cancer: a comprehensive review	142
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial	131
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer	122
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions	122
Issue Information	114
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer	105
Issue Information	101
	101

	87
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study	83
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward	77
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h	77
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence	76
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity	74
N ⁶ ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas	73
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of	73
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer	72
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer	69
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica	69
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses	67
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism	66
Cover Image, Volume 45, Issue 6	65
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials	65
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma	63
FOXO1 or not FOXO1: that is the question	62
Issue Information	59
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia	58
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression	58
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML	57
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma	56
Ubiquitination in cancer: mechanisms and therapeutic opportunities	53
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades	53
Harnessing chimeric antigen receptor macrophages against solid tumors	52
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene	52